Herpes zoster was well known to the Ancient Greeks (erpo, creep; zoster, a girdle) and in Roman times the term zona was used by Pliny of the eruption. It was not, however, until 1865 that von Barensprung noted the association of herpes zoster with a lesion of the posterior root ganglion, an observation confirmed two years later in the trigeminal ganglion by Hutchinson2 and by Bowman3. In 1953 Weller4 proved what had long been suspected that varicella-zoster virus (VZV) has a causal role in the disease. The current theory is that, after an initial attack, virus remains latent in the dorsal root ganglion until reactivated, whereupon it migrates down the sensory nerve to cause perineuritis, perivasculitis and neuronal death. In this paper I focus on ophthalmic herpes zoster.
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VIRUS ACQUISITION AND LATENCY
After the original attack of chickenpox, thought to be acquired by droplet infection, VZV passes from the vesicles down the sensory nerves to the neural cell body and satellite cells, where viral genome is incorporated in host genome. There is little cellular disruption; it may constitute pure symbiosis or the virus may become reactivated sporadically but be contained by the body's defences. In ophthalmic herpes zoster, the reactivated VZV travels down the ophthalmic nerve from the trigeminal ganglion, taking [3] [4] days to reach the nerve endings. When VZV RNA or DNA has been sought post mortem in trigeminal ganglia it has been detected in almost all cases where the individual was seropositive for the virus, about one in a thousand neurons being affected5. 95% of the adult population are seropositive6, though a smaller proportion can recall an attack of chickenpox or zoster. By the age of 80, up to 50% of people who have had chickenpox will develop zoster7. REACTIVATION What might account for the reactivation of VZV in dorsal root ganglia? Various hypotheses have been offered.
Trauma
Mild and transient attacks of herpes zoster sometimes follow retrobulbar or trigeminal ganglion injections and neurosurgical incisions so-called symptomatic zoster. In adults, neuronal metabolism is largely concerned with Moorfields Eye Hospital, City Road, London EC1V 2PD, UK maintenance of the cells and there is virtually no proliferative activity: most of the DNA is inactive. If the cell is damaged in some way (e.g. by cutting of the axon), repair mechanisms begin, and it is conceivable that viral DNA becomes involved in this process, with a switching-on of viral proliferation which may or may not overwhelm the cell and lead to viral shedding8.
Ageing
Most episodes of zoster are seen in the old and cannot be related to a precipitant. It is possible that a latently infected cell is affected, directly or indirectly, by the normal neuronal death rate (apoptosis). Thus, a fall-off of neurotrophic factors might set off the process of reactivation an intellectually satisfying idea for which there is as yet no evidence. Also there is progressive loss of the regulatory control of T lymphocytes: after the age of 65 they become much less responsive in culture to varicella antigen than lymphocytes from young people9. Against this hypothesis is the fact that zoster can present at any time of life. COURSE Ocular disease comes in three phases-acute, chronic and relapsing. Acute lesions of the globe and orbit develop within 3 weeks of the rash. They may rapidly and completely resolve but can lead to a chronic course, especially if untreated, and linger for years. Alternatively, acute lesions may appear to clear but then relapse years after the disease onset. Recurrence is a particularly distinctive feature of the disease. Complications fall primarily into those associated with inflammatory changes, those resulting from nerve damage, and those secondary to tissue scarring. Inflammatory changes may be in the form of infiltration in dendritic, nummular and disciform keratitis or a vasculitis in the case of episcleritis/scleritis, iritis, ischaemic papillitis and orbital vasculitis. Conditions resulting from nerve damage include neurotrophic (neuroparalytic) keratitis, some ocular motor palsies and neuralgia. Those subsequent to tissue scarring are lid deformities, neuralgia and lipid keratopathy.
Onset
There is a prodromal flu-like illness with headache, pyrexia, malaise, depression, and sometimes neck stiffness, lasting up to a week before the rash appears and probably associated with a limited viraemia. This is followed shortly by localized pain over the distribution of the ophthalmic nerve, lymph node swelling in the corresponding drainage areas, and, occasionally, a red eye (probably due to virally induced inflammation in the ganglion and ophthalmic nerve). The localized pain precedes the rash by several days in some cases.
Rash
Crusts start to form from about 6 days onwards and virus cannot be cultured from them. All, or just one, of the cutaneous branches of the ophthalmic nerve may be affected. Occasionally the lesions are large, confluent, and deep with haemorrhagic bullae (perhaps due to a vasculitis in the dermal papillael') and lead to severe tissue ischaemia.
Chronic skin changes are due to ischaemia, and vasomotor abnormalities may give the false impression of a recurrent rash. Hutchinson's rule is that cutaneous involvement of the nasociliary nerve heralds ocular complications; this has proved correct. However, severe ocular complications can occur with a very mild insignificant rash anywhere on the forehead. Indeed there seems to be an arbitrary spread of virus. Table 1 summarizes the ocular complications and  Table 2 the neuro-ophthalmic complications.
Recurrent ocular disease
Perhaps the most puzzling aspect of ophthalmic herpes zoster is the recurrent nature of the ocular complications, which can reappear as late as 10 years after the onset of the disease. They seem unrelated to the severity of the initial disease but are often precipitated by sudden stopping or reduction of topical steroid. Steroid dependence and poor response to systemic and topical acyclovir suggest some autoimmune process.
PATHOGENESIS OF ZOSTER
Virus replication in the trigeminal ganglion is rapidly followed by a perineuritis and perivasculitis; the virus then seems to disappear and necrosis of neural and other tissues evolves, sometimes evident at necropsy many years later' . Virology VZV is a typical herpesvirus incorporating DNA in an icosahedral nucleocapsid and a glycoprotein-containing outer membrane (Figure 1 ). The tegument situated between the nucleocapsid and envelope is an amorphous protein structure important in inducing active viral transcription in the nucleus and shutting off the host protein production. The capsid consists of capsomeres the susceptible cells and also contain antigenic determinants. Only enveloped virions get into cells and initiate replication. Some gene functions have been elucidated and these are important in understanding of viral replication and antiviral therapy. There is probably an early phase (concerned with regulatory function), an intermediate phase (concerned with DNA synthesis), and a late phase (concerned with capsid and membrane synthesis). Many VZV proteins are involved in replication, including the enzymes thymidine kinase and thymidylate synthetase and a range of DNA binding proteins including DNA polymerase and several immediate-early transcriptional regulators.
Immunity
Hope-Simpson12 suggested that, when the titres of antibody or reactive cells fall below a certain level, the virus somehow escapes and causes clinical damage. There is no good evidence for this in man.
The immune response is both humoral and cellular. During an attack of herpes zoster, varicella neutralizing antibody rises quickly, typically within 2 days of rash onset, reaching a peak at 2-3 weeks, and declining to very low levels at a year'3. Circulating antigen-antibody complexes were detected in serum from 50% of a group of otherwise healthy individuals with localized zoster'4, and these may be part of the mechanism of vasculitis and tissue damage. Antibodies interfere with attachment of viruses to cells and agglutinate them. They also participate in the cytotoxic actions of macrophages, killer cells and polymorphonuclear leucocytes. Nevertheless, patients without antibody (agammaglobulinaemia) do not suffer from devastating zoster.
What of cellular immunity? In the first 5 days of a zoster rash it is consistently depressed'5. This could either be a true depression of cell-mediated immunity or the result of recruitment of immunologically competent cells into affected tissues so they are not available in the circulatory pool. Cytotoxic T cells are important in destroying virally affected cells and are probably the host defenders against reactivation of VZV. These cells can become activated when their receptor recognizes viral antigens (VZV glycoproteins, gpl-V and the immediate early tegument protein) binding with class I HLA antigens on the infected cell surface. Activation of cytotoxic T cells (CD8+) results in target cell death by membrane cell lysis after secretion of substances such as perforin. Helper CD4+ cells are necessary for the maturation of cytotoxic CD8+ T cells and for the production of specific neutralizing antibody by B cells maturing into plasma cells. Because Unlike deficient humoral immunity, depressed cellmediated immunity can lead to very severe zoster as witnessed in reticuloses, the rare hereditary cellular immunity defects'6 and AIDS. In these states the rash emerges in repeated crops, is severer than normal and frequently spreads to the rest of the body. Indeed, when a patient with zoster has more than 10 vesicles in other dermatomes the possibility of depressed cell-mediated immunity should be investigated. Also, patients with socalled pre-AIDS are prone to zoster and in a series from Rwanda all patients aged under 40 with ophthalmic zoster were seropositive for human immunodeficiency virus17. In the UK most patients with ophthalmic zoster are otherwise healthy and only those with HIV risk factors should be routinely investigated'8.
Mechanisms of damage
Why is zoster so severe in some patients and so trivial in others? On first principles it depends on the virulence of the virus, quantity of virus and host resistance. Susceptibility of cells to the virus depends on factors including the adsorption of virus onto the cell, the release of its nucleic acid, the age of the patient and the apparent preference of VZV for neural tissue. Host resistance preventing the establishment of infection and interfering with virus replication-depends on non-specific factors such as the physical barrier of intact epithelium, phagocytosis, interferon, pyrexia and low pH in surrounding tissues. Specific factors include immunoglobulins, T lymphocytes, macrophages and natural killer cells. Damage is produced by deposition of immune complexes and lysis of virally infected cells. The inflammatory response can do harm by releasing vasoamines and cytokines, and by interfering with intravascular anti-clotting mechanisms.
TREATMENT AND PROPHYLAXIS Antiviral treatment is based on interference with adsorption (heparin), penetration (amantadine) uncoating (chloroquine), genome synthesis (virustatics) and assembly (rifampicin). Virustatics are the most popular in practice, most of them interfering with viral thymidine kinase and DNA polymerase. A new generation of more potent antivirals, famivir and valciclovir, have replaced acyclovir. Because viral replication is short-lived and confined to the very onset of the disease they have to be delivered very early to have any effect. Initially they were claimed to reduce postherpetic neuralgia and ocular complications'9-21 but later results are more equivocal22'23. Topical acyclovir seems to have no effect on the eye complications.
Antiinflammatories act by inhibiting the activity of lymphocytes and macrophages. Why tarsorrhaphy and druginduced ptosis are so successful in neurotrophic keratitis is difficult to construe, but continuous intimate contact between the very vascular upper subtarsal conjunctiva and the cornea may allow diffusion of important trophic factors.
What of vaccines against HSV? The effects on development of zoster are as yet unknown, but prevention 673 JOURNAL OF THE ROYAL SOCIETY OF MEDICINE Volume 90 Dec e m be r 1 99 7 of varicella in childhood might be expected to confer protection; and, even in those with latent virus, regular boosting of immunity might forestall reactivation.
CONCLUSIONS
The major obstacles to research are the lack of a satisfactory animal model, the dearth of pathological material and the difficulty of obtaining cell-free virus. We need better understanding of the immune and inflammatory responses and how to modify them beneficially. What is going on in the chronic and relapsing lesions? Is there continuing viral replication or is it mainly a process of autoimmunity? Then there is the difficulty of diagnosing the disease early: even at the onset of the rash much neuronal and tissue damage has occurred, so we cannot expect much benefit from antivirals. This particularly applies to post-herpes neuralgia, neuropathic keratitis and vasculitis. Most inflammatory lesions respond well to steroids but, except in patients with depressed cell-mediated immunity, their response to acyclovir has been disappointing. In the long term, the best hope lies in VZV vaccination.
